Essais liés11clinical trials
VilleMorgantownlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT04539964

Ouvrir le site du centre

Essais cliniques associés

11
MoléculeIndication / populationPhaseNCTTitreStatut
Obinutuzumab Cancer Phase 3 NCT06084936 GLOBRYTE — A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma RECRUITING
Inavolisib Cancer Phase 2 NCT07054190 A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer RECRUITING
Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated Hypertension Non applicable NCT06059638 BACKBEAT — BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT RECRUITING
Implant Procedure SEP Phase 3 NCT04539964 RESET-RA — Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis ACTIVE_NOT_RECRUITING
Prasinezumab Parkinson Phase 3 NCT07174310 PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease RECRUITING
Implant Procedure SEP Non applicable NCT06796504 The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study RECRUITING
Diabetes and Hypertension Self Management Program Hypertension NA NCT06034548 Diabetes and Hypertension Self Management Program COMPLETED
Atogepant 60 mg Migraine Phase 4 NCT06972056 Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study RECRUITING
Renal Denervation (Symplicity Spyral™) Hypertension Non applicable NCT05198674 SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN ACTIVE_NOT_RECRUITING
Middle Meningeal Artery embolization Migraine Non applicable NCT06735833 MMA Embolization for Refractory Chronic Migraine RECRUITING
Fenebrutinib SEP Phase 3 NCT04544449 FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis ACTIVE_NOT_RECRUITING